🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "huge turning point" in the fight against increasingly resistant strains of the pathogen, according to health experts.

A Worldwide Health Concern

Cases of gonorrhoea are increasing around the world, with figures suggesting more than 82 million infections each year. Especially elevated rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an important and timely advancement in the reality of growing infection rates, escalating drug resistance and the very limited treatment choices at this time.”

Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The WHO has listed it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Receive Authorization

Zoliflodacin, also known as Nuzolvence, was approved by the American regulatory agency in December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers hope that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This drug, which is employed against urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a unique collaborative effort for medication research. The non-profit organisation GARDP collaborated with the drug firm Innoviva to develop it.

“This approval marks a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Clinical Trial Results and Global Access

According to results detailed in a prominent scientific publication, zoliflodacin cured the vast majority of cases of the STI. This puts it on an similar efficacy with the typical regimen, which combines a dual-drug approach. The research involved hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the rights to register and commercialise the drug in many regions with limited resources.

Clinicians on the front lines have expressed positive views. Access to a one-pill regimen such as this is described as a "critical tool" for managing the epidemic. This is deemed essential to lessen the impact of the disease for individuals and to stop the proliferation of highly drug-resistant gonorrhoea around the world.